Database

Startups

Main Industry
Biotechnology
Main Product/Service
1. CTC Detection System
2. NK Cell Expansion Kit
3. MSC Expansion Kit
4. Anti-EpCAM Monoclonal Antibody
5. EPCAM-FITC
Founded Year
2017
Unified Business No.
55734941
Status
Active
Number of Employees
0
Total Paid-in Capital
39,000,000 (NT$)
Location of Company
Taiwan , Hsinchu County
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
BioMab, Inc. is an immune-based precision medicine company based in Taiwan. Spun-out of Academia Sinica, our current product portfolio focuses on two primary areas of precision medicine: circulating tumor cell (CTC) and cell therapy.



More ↓

Similar Companies

EVERFRONT BIOTECH INC.

1. EF-001 (Cerebraca® Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011

Rephlmmune Biotechnology Inc.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and

ARCE THERAPEUTICS, INC.

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)